000			03247nam a2200277 4500
001			ESSALUD
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aBarco, Stefano _eAutor _954060
245			_aSirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease
300			_apáginas: 561-570
520			_aBackground: Whether sirolimus-coated balloon angioplasty for infrainguinal artery disease reduces the incidence of major adverse limb events remains unknown. Methods: In this prospective, open-label, noninferiority trial with a prespecified sequential testing strategy for superiority and blinded outcome adjudication, we randomly assigned patients with infrainguinal artery disease in a 1:1 ratio to undergo angioplasty with a sirolimus-coated balloon or with an uncoated balloon. The primary outcome was a composite of unplanned major amputation affecting the target limb or endovascular or surgical revascularization of the target lesion for critical limb ischemia within 1 year after randomization. The key secondary outcome was a composite of any unplanned amputation affecting the target limb or revascularization of the target lesion for critical or noncritical limb ischemia within 1 year after randomization. The noninferiority margin was 5 percentage points. The primary safety outcome was death from any cause within 1 year after randomization. Results: A total of 1252 patients were enrolled in the trial: 626 patients were assigned to the sirolimus-coated–balloon group and 626 to the uncoated-balloon group. The median age of the patients was 75 years, and 35.1% were women. A primary-outcome event occurred in 55 patients (8.8%) in the sirolimus-coated–balloon group and in 94 patients (15.0%) in the uncoated-balloon group (median unbiased estimate of risk difference, −4.9 percentage points; 95% confidence interval [CI], −8.5 to −1.3; P<0.001 for noninferiority; P=0.009 for superiority); a key secondary-outcome event occurred in 144 patients (23.0%) and 193 patients (30.8%), respectively (risk difference, −7.8 percentage points; 95% CI, −12.7 to −2.9; P=0.002). Death occurred in 74 patients (11.8%) in the sirolimus-coated–balloon group and in 80 patients (12.8%) in the uncoated-balloon group (risk difference, −1.0 percentage points; 95% CI, −4.6 to 2.7; P=0.67). The incidence of adverse events appeared to be similar in the two groups. Conclusions: Among patients with infrainguinal artery disease undergoing endovascular treatment, angioplasty with sirolimus-coated balloons led to a lower incidence of major adverse limb events at 1 year than angioplasty with uncoated balloons.
650			_aCARDIOLOGÍA _911301
650			_aENFERMEDAD ARTERIAL PERIFÉRICA AORTICA _954061
650			_aANGIOPLASTIA _937212
700			_aEngelberger, Rolf P. _954062
700			_aHeld, Ulrike _954063
700			_aFumagalli, Riccardo M. _954064
700			_aGrigorean, Alexandru _954065
700			_aHayoz, Daniel _954066
700			_aMünger, Mario _954067
773	0		_022717 _922644 _dMassachusetts NEJM Group _oNEJM009 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-08-14 _zSQB
999			_c22814 _d22814